MARKET

RDHL

RDHL

Redhill Biopharm
NASDAQ
1.030
0.000
0.00%
After Hours: 0.9601 -0.0699 -6.79% 19:59 12/31 EST
OPEN
1.000
PREV CLOSE
1.030
HIGH
1.040
LOW
0.9050
VOLUME
318.83K
TURNOVER
--
52 WEEK HIGH
6.98
52 WEEK LOW
0.9050
MARKET CAP
5.25M
P/E (TTM)
-0.4498
1D
5D
1M
3M
1Y
5Y
1D
RedHill Biopharma Files Pro Forma Financials After Talicia Joint Venture Deal With Cumberland
TipRanks · 12/31/2025 22:17
Weekly Report: what happened at RDHL last week (1222-1226)?
Weekly Report · 12/29/2025 10:05
Redhill Biopharma Granted U.S. Patent #12,502,381 Titled "SERINE PROTEASE INHIBITOR FOR TREATING CORONAVIRUS INFECTION"
Benzinga · 12/23/2025 18:06
RedHill Biopharma Secures Up to $25 Million Standby Equity Facility with YA II PN
TipRanks · 12/23/2025 12:27
Weekly Report: what happened at RDHL last week (1215-1219)?
Weekly Report · 12/22/2025 10:05
RedHill Biopharma’s Opaganib Shows Promise in Combating CLL Resistance
TipRanks · 12/15/2025 12:27
RedHill Biopharma Shared In Vivo Results, Indicating That Opaganib Combined With Venetoclax Reduces Chronic Lymphocytic Leukemia Cells By Half Compared To Controls
Benzinga · 12/15/2025 12:20
RedHill Biopharma announces in vivo results on opaganib, venetoclax
TipRanks · 12/15/2025 12:10
More
About RDHL
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.

Webull offers RedHill Biopharma Ltd (ADR) stock information, including NASDAQ: RDHL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RDHL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RDHL stock methods without spending real money on the virtual paper trading platform.